Larimar Therapeutics, Inc. current report, 13 June 2019

Business Context and Reporting Period

This Form 8-K filing by Zafgen, Inc. (trading symbol ZFGN) reports on the Annual Meeting of Stockholders held on June 13, 2019. The record date for the meeting was April 22, 2019, with 37,326,895 outstanding shares of common stock. Note: The input metadata references "Larimar Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Zafgen, Inc.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.

Material Changes and Voting Results

Stockholders voted on two primary proposals:

  • Proposal 1 (Director Election): Stockholders approved the election of Peter Barrett, Ph.D., and Wendy Everett, Sc.D., as Class II directors for three-year terms.
  • Proposal 2 (Auditor Ratification): Stockholders approved the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.

Voting Breakdown for Directors:

Nominee For Withhold Broker Non-Votes
Peter Barrett, Ph.D. 20,445,938 5,015,834 6,746,897
Wendy Everett, Sc.D. 20,850,967 4,610,805 6,746,897

Voting Breakdown for Auditor Ratification:

  • For: 31,893,884
  • Against: 295,150
  • Abstain: 19,635

Guidance, Outlook, and Risks

The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.

Key Facts for Investor Verification

  • Verify the company name discrepancy between the metadata (Larimar Therapeutics) and the filing (Zafgen, Inc.).
  • Confirm the tenure of the newly elected Class II directors (Peter Barrett and Wendy Everett) expires in 2022.
  • Note the significant number of broker non-votes (6,746,897) on the director election, which did not affect the outcome but indicates a portion of shares were not voted on this matter.
  • Review the Definitive Proxy Statement filed on April 26, 2019, for detailed background on the nominees and auditor appointment.